ReviewInvestigative and clinical urology2020
Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis.
Review in Investigative and clinical urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Pooled it
- Diagnostic and therapeutic cystoscopy in bladder pain syndrome/interstitial cystitis: systematic review of literature and consensus on methodology.International urogynecology journal · 2023Pooled it
- An indirect comparison meta-analysis of noninvasive intravesical instillation and intravesical injection of botulinum toxin-A in bladder disorders.International urology and nephrology · 2022Pooled it
- A single-center, phase 1/2a trial of hESC-derived mesenchymal stem cells (MR-MC-01) for safety and efficacy in interstitial cystitis patients.Stem cells translational medicine · 2025Trial
- Urodynamic Changes Following Fewer Injection Sites of Intravesical Botulinum Toxin in Idiopathic Detrusor Overactivity: A Double-Blinded Prospective Randomized Clinical Trial.International urogynecology journal · 2025Trial
- Article
- Botulinum Toxin Therapy: A Comprehensive Review on Clinical and Pharmacological Insights.Journal of clinical medicine · 2025Review
- Efficacy of 100-U Onabotulinumtoxin A Treatment in Female Idiopathic Overactive Bladder-A Prospective Follow-Up Study.International urogynecology journal · 2025Article
- Wearable Temperature Sensor Enhanced Volatilomics Technique for Swift and Convenient Detection of Latrogenic Botulism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Botulinum toxin improved intestinal adaptation to short gut in a twenty-one-day-old weanling rat.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Article
- Article
- Improving intravesical botulinum toxin-A injection technique: Reshaping the needle may benefit more.Investigative and clinical urology · 2024Article
- Article
- A Discrete Mathematics Approach for Understanding Risk Factors in Overactive Bladder Treatment.Cureus · 2024Article
- Bladder instillation patterns in a cohort of women with interstitial cystitis/bladder pain syndrome.Urogynecology (Philadelphia, Pa.) · 2023Article
- Intravesical Injection of Abobotulinumtoxin-A in Patients with Bladder Pain Syndrome/Interstitial Cystitis.Urology research & practice · 2023Article
- Onabotulinum Toxin A Intradetrusor Injections in Children with Neurogenic Lower Urinary Tract Dysfunction: Long-Term Histological Effects on the Bladder Wall.Biomedicines · 2023Article
- Article
- Article
- Single-cell RNA sequencing reveals the immune microenvironment and signaling networks in cystitis glandularis.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After decades of clinical and basic science research, the clinical application of botulinum toxin A (Botox) in urology has been extended to neurogenic detrusor overactivity (NDO), idiopathic detrusor overactivity, refractory overactive bladder (OAB), interstitial cystitis/bladder pain syndrome (IC/BPS), lower urinary tract symptoms, benign prostatic hyperplasia, and neurogenic or non-neurogenic lower urinary tract dysfunction in children. Botox selectively disrupts and modulates neurotransmission, suppresses detrusor overactivity, and modulates sensory function, inflammation, and glandular function. In addition to motor effects, Botox has been found to have sensory inhibitory effects and anti-inflammatory effects; therefore, it has been used to treat IC/BPS and OAB. Currently, Botox has been approved for the treatment of NDO and OAB. Recent clinical trials on Botox for the treatment of IC/BPS have reported promising therapeutic effects, including reduced bladder pain. Additionally, the therapeutic duration was found to be longer with repeated Botox injections than with a single injection. However, the use of Botox for IC/BPS has not been approved. This paper reviews the recent advances in intravesical Botox treatment for OAB and IC/BPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.